Saint Francis Hospital and Medical Center
The Mandell MS Center

 

Host to the Multiple Sclerosis Brain Symposium 2016 | About Joyce and Andy Mandell

 

Responsiveness to Dalfampridine Treatment Among Multiple Sclerosis Patients Followed at the Mandell Multiple Sclerosis Center

ClinicalTrials.gov Identifier: NCT01399957 

Location
Mount Sinai Hospital
490 Blue Hills Ave
Hartford, CT 06112

Short Description

Ampyra (dalfampridine) has been approved by the FDA for improving walking speed in persons with multiple sclerosis (MS). This observational study was designed to capture information on additional possible benefits person’s taking Ampyra may or may not experience. This project seeks to determine factors that will predict a response (an increase in walking speed) to dalfampridine.  A second goal is to identify possible additional benefits to taking Dalfampridine. 

Status  Closed to enrollment, in data analysis phase only.

Principal Investigators Albert Lo, MD, PhD, and Elizabeth Triche, PhD

Contact Kayla Olson, Study Coordinator

Phone (860) 714-2149

 

The Mandell MS Center
490 Blue Hills Avenue
Hartford, CT 06112
860-714-2149